You are currently viewing a new version of our website. To view the old version click .

Topic Information

Dear Colleagues,

Over the past years, the availability of high-throughput technologies has led to an important change in pharmacogenetics, improving the practice of precision medicine. The tumour genetic landscape influences treatment response in cancer patients. Multiple molecular mechanisms of resistance to therapies in solid or hematologic tumours have been discussed, highlighting the degree of tumours’ heterogeneity. Multiple approaches, using liquid biopsies, circulating tumour cells and tissue biopsies, can be helpful to monitor patients during therapy and understand drug resistance mechanisms. This knowledge has paved the way for the development of personalized medicine aimed at providing better clinical and therapeutic approaches. To this end, there is an urgent need for the identification of predictive biomarkers of response/resistance to treatments and toxicity, including new tools for genome analysis for the development of personalized medicine. We are pleased to invite you to contribute to our Topic entitled “Pharmacogenetics: A Tool in Cancer Therapy” aimed to collect contributions on the potential role of Pharmacogenetics in cancer treatment, also highlighting the strength as well as its limits in clinical translation. This Topic aims to investigate the different pharmacogenetics approaches useful to identify potential biomarkers in cancer therapy. In this Topic, original research articles and reviews are welcome.

Research areas may include (but are not limited to) the following:

  • Genetic variability related to drug toxicity and efficacy in cancer;
  • Genomic and proteomic profiling in cancer;
  • ncRNA profiles to predict prognosis and outcome in cancer;
  • Liquid biopsy in cancer;
  • Methylation profiles to predict cancer prognosis and outcome;
  • Multi-omics approaches to the study of cancer treatment response;
  • Epigenetic changes as determinants of drug response and resistance in cancer;
  • Novel genomic targets for drug development.

I/We look forward to receiving your contributions.

Dr. Stefania Crucitta
Dr. Gloria Ravegnini
Dr. Rossana Roncato
Topic Editors

Keywords

  • pharmacogenetics
  • pharmacogenomics
  • target therapy
  • cancer therapy
  • personalised medicine
  • solid tumour
  • haematologic tumour
  • liquid biopsy
  • treatment toxicity

Participating Journals

Cancers
Open Access
34,550 Articles
Launched in 2009
4.4Impact Factor
8.8CiteScore
19 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
International Journal of Molecular Sciences
Open Access
106,602 Articles
Launched in 2000
4.9Impact Factor
9.0CiteScore
18 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Journal of Personalized Medicine
Open Access
7,567 Articles
Launched in 2011
-Impact Factor
6.0CiteScore
25 DaysMedian Time to First Decision
-Highest JCR Category Ranking
Onco
Open Access
135 Articles
Launched in 2021
-Impact Factor
-CiteScore
24 DaysMedian Time to First Decision
-Highest JCR Category Ranking
Pharmaceuticals
Open Access
9,956 Articles
Launched in 2004
4.8Impact Factor
7.7CiteScore
16 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking

Published Papers